These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29127952)

  • 1. Diabetes mellitus in a patient with glycogen storage disease type Ia: a case report.
    Cohn A; Ohri A
    J Med Case Rep; 2017 Nov; 11(1):319. PubMed ID: 29127952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report.
    Katayama D; Baba H; Kuwabara T; Kido J; Mitsubuchi H; Matsumoto S; Nakamura K
    J Med Case Rep; 2021 Feb; 15(1):75. PubMed ID: 33588940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary diabetes as a rare complication of glycogen storage disease 1a: case report and review of literature.
    Aggarwal A; Patel D; Kulshreshtha B
    Pediatr Endocrinol Diabetes Metab; 2021; 27(4):283-286. PubMed ID: 35114770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
    Maiorana A; Tagliaferri F; Dionisi-Vici C
    Front Endocrinol (Lausanne); 2023; 14():1145111. PubMed ID: 37152929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.
    Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Ways K; Desai M; Shaw W; Capuano G; Alba M; Jiang J; Vercruysse F; Meininger G; Matthews D;
    Diabetes Care; 2015 Mar; 38(3):403-11. PubMed ID: 25468945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type la glycogen storage disease complicated with diabetes mellitus: the role of flash continuous glucose monitoring.
    Marcalo J; Oliveira A; Nunes PA; do Vale S
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33766968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of postprandial endogenous insulin secretion rather than exogenous insulin injection ameliorated insulin antibody-induced unstable diabetes: a case report.
    Kaneko K; Satake C; Izumi T; Tanaka M; Yamamoto J; Asai Y; Sawada S; Imai J; Yamada T; Katagiri H
    BMC Endocr Disord; 2019 Jan; 19(1):5. PubMed ID: 30621663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of glycogen storage disease type I associated with an incomplete type of Fanconi syndrome; the protective role of lysosomal alpha 1,4-glucosidase and insulin deficiency against hypoglycemia.
    Itakura M; Yamashita N; Fujita T; Koide Y; Kugai N; Yamamura H; Yamashita K
    Horm Metab Res; 1984 Dec; 16 Suppl 1():204-6. PubMed ID: 6398262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA; Saboo BD; Dodiya HG; Rao SK; Joshi SR; Modh VB; Ghadiya SV
    Diabetes Metab Syndr; 2016; 10(2):88-91. PubMed ID: 26777258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA; Sloan L
    Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypoglycemia due to antibodies to exogenous insulin in a patient with type 2 diabetes – a case report of treatment with new generation oral hypoglycemic agents].
    Ucieklak D; Zięba-Parkitny J; Kozek E; Skupień J; Sztefko K; Małecki MT
    Przegl Lek; 2017; 74(1):41-3. PubMed ID: 29694001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of hypoglycaemia in a patient with type Ib glycogen storage disease by an amylase (alpha-glucosidase) inhibitor.
    Ihara K; Kuromaru R; Ryu A; Fukushige J; Hara T
    Acta Paediatr; 1998 May; 87(5):595-8. PubMed ID: 9641747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A glycogen storage disease type 1a patient with type 2 diabetes.
    Sun Y; Qiang W; Wu R; Yin T; Yuan J; Yuan J; Gu Y
    BMC Med Genomics; 2022 Sep; 15(1):205. PubMed ID: 36167523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
    Munir KM; Davis SN
    Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.